EGFR and non-small cell lung carcinoma: Among non-small cell lung cancer patients, approximately 30%–40% of Asian patients have EGFR mutations (Herbst et al., 2008), approximately 90% of which are exon 19 deletion mutations (Del19) and exon 21 L858R mutations, accounting for 44%–51% and 38%–40% (Reita et al., 2021) of all mutations, respectively.